Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Vertex Pharmaceuticals Inc (VRTX)  
$483.04 8.09 (1.7%) as of 4:30 Wed 6/5


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 260,040,000
Market Cap: 125.61(B)
Last Volume: 1,196,632 Avg Vol: 1,608,800
52 Week Range: $323.62 - $456.95
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     NASDAQ-100
    S&P 400 MIDCAP     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  543
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 34,832 156,170 271,197 631,666
Total Sell Value $15,561,839 $65,781,555 $107,325,701 $215,119,054
Total People Sold 10 13 14 18
Total Sell Transactions 12 45 68 135
End Date 2024-03-07 2023-12-05 2023-06-06 2022-06-06

   
Records found: 3282
  Page 5 of 132  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Leiden Jeffrey M Executive Chairman   •       •      –    2024-02-07 4 A $0.00 $0 D/D 7,707 41,046     -
   Ambrose Kristen SVP & Chief Accounting Officer   •       –      –    2024-02-07 4 A $0.00 $0 D/D 1,853 11,641     -
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2024-02-06 4 A $0.00 $0 D/D 14,842 63,479     -
   Kewalramani Reshma CEO & President   •       •      –    2024-02-06 4 A $0.00 $0 D/D 41,488 150,199     -
   Wagner Charles F Jr EVP & Chief Financial Officer   •       –      –    2024-02-06 4 A $0.00 $0 D/D 15,254 58,947     -
   Bozic Carmen EVP and CMO   •       –      –    2024-02-06 4 A $0.00 $0 D/D 13,680 42,982     -
   Sachdev Amit EVP Chief Patient & Ext Af Off   •       –      –    2024-02-06 4 A $0.00 $0 D/D 13,680 72,494     -
   Altshuler David EVP, Global Research and CSO   •       –      –    2024-02-06 4 A $0.00 $0 D/D 13,680 45,718     -
   Arbuckle Stuart A EVP, COO   •       –      –    2024-02-06 4 A $0.00 $0 D/D 18,186 74,742     -
   Biller Jonathan EVP and Chief Legal Officer   •       –      –    2024-02-06 4 A $0.00 $0 D/D 6,294 16,863     -
   Atkinson Edward Morrow Iii EVP, Chief Technical Ops. Off.   •       –      –    2024-02-06 4 A $0.00 $0 D/D 6,260 20,139     -
   Leiden Jeffrey M Executive Chairman   •       •      –    2024-02-06 4 A $0.00 $0 D/D 30,916 33,339     -
   Ambrose Kristen SVP & Chief Accounting Officer   •       –      –    2024-02-06 4 A $0.00 $0 D/D 2,950 9,788     -
   Leiden Jeffrey M Executive Chairman   •       •      –    2024-01-08 4 AS $419.07 $2,785,977 D/D (6,648) 2,423 6%     
   Wagner Charles F Jr EVP & Chief Financial Officer   •       –      –    2024-01-02 4 AS $405.00 $1,215,000 D/D (3,000) 43,693 5%     
   Kewalramani Reshma CEO & President   •       •      –    2023-12-15 4 AS $407.00 $6,973,945 D/D (17,135) 108,711 -4%     
   Kewalramani Reshma CEO & President   •       •      –    2023-12-15 4 OE $155.57 $3,115,593 D/D 17,135 125,846     -
   Leiden Jeffrey M Executive Chairman   •       •      –    2023-12-13 4 AS $399.41 $5,333,799 D/D (13,354) 9,071 -2%     
   Arbuckle Stuart A EVP, COO   •       –      –    2023-12-13 4 AS $399.00 $3,432,597 D/D (8,603) 56,556 -2%     
   Arbuckle Stuart A EVP, COO   •       –      –    2023-12-13 4 OE $187.53 $1,613,321 D/D 8,603 65,159     -
   Kewalramani Reshma CEO & President   •       •      –    2023-12-13 4 AS $397.00 $2,023,906 D/D (5,098) 108,711 -2%     
   Thornberry Nancy Director   –       •      –    2023-12-05 4 A $0.00 $0 D/D 1,136 1,136     -
   Wagner Charles F Jr EVP & Chief Financial Officer   •       –      –    2023-11-20 4 AS $349.88 $1,049,640 D/D (3,000) 46,693 15%     
   Sachdev Amit EVP Chief Patient & Ext Af Off   •       –      –    2023-11-15 4 AS $369.92 $12,947 D/D (35) 58,814 19%     
   Altshuler David EVP, Global Research and CSO   •       –      –    2023-11-15 4 AS $369.92 $7,028 D/D (19) 32,038 19%     
  3282 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 5 of 132
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us